Great Point Partners LLC

Search
⚲

Great Point Partners LLC ✚
CRD #	158423
SEC #	801-73834
CIK #	0001281446
AUM	1,777.1 M (2026-03-31)
Employees	28 (82% Investors, 14% Brokers)
Fees
Minimum
Phone	203-971-3300
Address	165 Mason Street Greenwich, CT 06830
Source	[IAPD] [EDGAR] [Website] [LinkedIn]

Total AUM ($B) Copy

CIK	Period
0001281446	2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31

CIK

Period

0001281446

Sector	Form 13F Holdings	Value ($M)
	Apogee Therapeutics Inc	31.5
	Vor Biopharma Inc	31.2
	JATT Acquisition Corp	25.1
	Amylyx Pharmaceuticals Inc	24.3
	Nantkwest Inc	23.0
	Nektar Therapeutics	22.8
	Sol-Gel Technologies Ltd	21.7
	Alumis Inc	18.9
	Bright Minds Biosciences Inc	16.1
	Annexon Inc	13.8
	Health Sciences Acquisitions Corp	13.6
	Aerovate Therapeutics Inc	13.6
	Contineum Therapeutics Inc	10.5
	Zenas Biopharma Inc	10.2
	Aquinox Pharmaceuticals Inc	10.1
	Helix Acquisition Corp	9.3
	Eliem Therapeutics Inc	9.1
	ARCA Biopharma Inc	9.0
	Eupraxia Pharmaceuticals Inc	8.7
	Vera Therapeutics Inc	8.0
	Evommune Inc	7.5
	LB Pharmaceuticals Inc	7.4
	Olivia Ventures Inc	7.1
	Scynexis Inc	6.9
	Neuralstem Inc	6.0
	Context Therapeutics Inc	5.9
	Camp Nine Inc	5.9
	Silence Therapeutics PLC	5.4
	Unicycive Therapeutics Inc	5.2


Prev \| Page 1 \| Next

Type	Form D Funds	Date	Sold	AUM
PE	GPP IV - Eutecma LLC	2026-03-31		1.0 M
PE	GPP IV - Lyocontract LLC	2025-03-28		77.7 M
PE	GPP IV - LUDI LLC	2024-10-14		4.6 M
PE	GPP - CF I LP	[2023-03-31]	36.4 M	25.6 M
	Offered $36,415,770 · Filed 2022-12-12 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose
PE	GPP III - Ephicacy LLC	2023-03-31		21.9 M
PE	GPP III - Ixcells LLC	2023-03-31		1.8 M
PE	Great Point Partners IV LP	[2022-05-05]	432.0 M	658.5 M
	Offered $500,000,000 · Filed 2022-04-15 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining $68,030,000 · Duration One year or less · Commission $680,000 · Revenue Decline to Disclose
PE	GPP III - PCM LLC	2022-03-31		40.2 M
PE	GPP II-A Salmon AIV LP	2021-02-25		20.6 M
PE	GPP III - MLM LLC	2021-02-25		5.4 M
View All

AUM Breakdown	Accounts	AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals)	0	0.0
(b) Individuals (high net worth individuals)	0	0.0
(c) Banking or thrift institutions	0	0.0
(d) Investment companies	0	0.0
(e) Business development companies	0	0.0
(f) Pooled investment vehicles	17	1.8
(g) Pension and profit sharing plans	0	0.0
(h) Charitable organizations	0	0.0
(i) State or municipal government entities	0	0.0
(j) Other investment advisers	0	0.0
(k) Insurance companies	0	0.0
(l) Sovereign wealth funds and foreign official institutions	0	0.0
(m) Corporations or other businesses not listed above	0	0.0
(n) Other	0	0.0
Total	17	1.8
By Discretionary
Discretionary	17	1.8
Non-Discretionary	0	0.0
Total	17	1.8
By Non-United States Persons
Non-United States Persons		0.2
United States Persons		1.6
Total	17	1.8

Form D Directors	Role	# Filings	# Firms
Riyaz Nooruddin	Director	61	22
Alan Kelly	Director	39	17
Charl Grobler	Director	7	5
Jeffrey Jay	Director, Executive Officer	12	2
David Kroin	Executive Officer	7	2
Great Point Partners LLC	Executive Officer, Promoter	3	2
Great Point GP LLC	Executive Officer	2	2
Great Point Partners CF I GP LLC	Promoter	1	1

EDGAR Form	CIK	2011 - 2026
13F-HR	[0001281446]
13F-NT	[0001281446]
3	[0001281446]
4	[0001281446]
SC 13D	[0001281446]
SC 13G	[0001281446]

Form 13D/13G Filer	Form 13D/13G Subject	Filed
Great Point Partners LLC	Amanat Acquisition Corp	[2026-05-27]
Great Point Partners LLC	Promis Neurosciences Inc	[2026-05-15]
Great Point Partners LLC	JATT II Acquisition Corp	[2026-04-24]
Great Point Partners LLC	Scynexis Inc	[2026-04-07]
Great Point Partners LLC	Sol-Gel Technologies Ltd	[2026-03-31]
Great Point Partners LLC	Vor Biopharma Inc	[2025-12-17]
Great Point Partners LLC	Inventiva Sa	[2025-06-20]
Great Point Partners LLC	ZURA Bio Ltd	[2025-05-14]
Great Point Partners LLC	Elevation Oncology Inc	[2024-08-15]
Great Point Partners LLC	Promis Neurosciences Inc	[2024-08-05]
View All

Firm Profile (Form ADV)
Discretionary AUM	$0.9B
Serves	Institutional
Fund Types	Hedge Fund, Private Equity

Form 3/4/5 Subject	2011 - 2026
Kroin David
Great Point Partners LLC
Foamix Pharmaceuticals Ltd
Jay Jeffrey R
Adamas Pharmaceuticals Inc
Apyx Medical Corp
Sheffield Ian
Great Point Partners I LP
Great Point Partners I GP LLC
Connecture Inc
View All

Insider Transaction (Form 3/4/5)	Date	Action	Shares	Price	Value ($)
Adamas Pharmaceuticals Inc ADMS Common Stock	2017-06-21	Sell	10,000	$17.44	174,400
Adamas Pharmaceuticals Inc ADMS Common Stock	2017-06-20	Sell	20,000	$17.35	347,000
Adamas Pharmaceuticals Inc ADMS Common Stock	2017-06-19	Sell	350,000	$17.05	5,967,500
Connecture Inc CNXR Common Stock	2015-06-30	Gift	10,000	$0.00
Connecture Inc CNXR Common Stock	2015-06-10	Other	1,375,733	$0.00
Connecture Inc CNXR Common Stock	2015-06-10	Other	39,703	$0.00
Connecture Inc CNXR Common Stock	2015-06-10	Other	47,235	$0.00
Connecture Inc CNXR Common Stock	2015-06-10	Other	36,493	$0.00
Connecture Inc CNXR Common Stock	2015-06-10	Other	28,696	$0.00
Apyx Medical Corp BVX Series B Convertible Preferred Stock · derivative	2015-03-17	Grant	3,588,139
Apyx Medical Corp BVX Common Stock	2015-03-17	Grant	480,000	$2.50	1,200,000
Apyx Medical Corp BVX Common Stock Warrants (right to buy) · derivative	2015-03-17	Disposed to issuer	5,250,000
Apyx Medical Corp BVX Series A Convertible Preferred Stock · derivative	2015-03-17	Disposed to issuer	3,500,000
Connecture Inc CNXR Series B Preferred Stock · derivative	2014-12-17	Conversion	17,696,553	$0.00
Connecture Inc CNXR Common Stock	2014-12-17	Sell	395,886	$8.00	3,167,088
Connecture Inc CNXR Common Stock	2014-12-17	Conversion	5,898,851
Apyx Medical Corp BVX Stock Option (Option to Buy) · derivative	2014-07-17	Grant	12,000	$0.00
WaferGen Bio-systems Inc WGBS Common Stock	2013-11-15	Conversion	899,893
WaferGen Bio-systems Inc WGBS Common Stock	2013-11-15	Conversion	899,893
WaferGen Bio-systems Inc WGBS Series 1 Convertible Preferred Stock · derivative	2013-11-15	Conversion	357.76
showing 20 of 39 most recent transactions

Comparable Firms	State	AUM
D2 Asset Management LP ✚	TX	1,825.9 M
ParaFi Capital LP ✚	NY	1,817.8 M
Tensile Capital Management LP ✚	CA	1,796.0 M
Morgan Creek Capital Management LLC ✚	NC	1,790.2 M
QVT Financial LP ✚	NY	1,786.7 M
Alta Park Capital LP ✚	CA	1,779.6 M
OFS Capital Management LLC ✚	IL	1,760.0 M
RCF Management LLC ✚	CO	1,757.0 M
Parkman Healthcare Partners LLC ✚	CT	1,744.0 M
Long Path Partners LP ✚	CT	1,732.8 M

Great Point Partners LLC

Assets, Funds, Holdings